Abstract: A device is described for facilitating the preparation of therapeutic foam e.g. for the treatment of varicose veins. A pressurised vial contains a sclerosant liquid, e.g., polidocanol solution, and a sterile gas which is readily absorbed by the body, e.g., carbon dioxide, oxygen or a mixture of these gases. The vial is provided either with a specialised stopper/seal into which a syringe nozzle may be inserted or alternatively a septum seal which may be penetrated by a hypodermic needle. The quantities of gas and liquid and the pressure in the vial are pre-set so that, on connection of a syringe to the vial, a predetermined volume of both gas and liquid is transferred to the syringe, with the intention that the syringe is then used to make a foam by known means. The use of the vial ensures that the ratio of gas to liquid in the foam is standardised, and also provides a convenient way of packaging the gas and liquid and of filling the syringe in a sterile manner.

Abstract: The present invention relates to the uses of swertiamarin or of a plant extract enriched with swertiamarin, for stimulating the formation or regeneration of the epidermis and/or for stimulating the metabolism of the dermis mainly in the cosmetics field.

Abstract: The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.

Abstract: Tattoo removal is disclosed. In an example, a method for removing tattoo ink from skin or resolving a medical condition related to tattoo ink, includes applying a primary solution of beta glucan to a treatment area having tattooed skin. The primary solution stimulates the skin in the treatment area to enhance removal of the tattoo ink from the skin. The example method also includes coating the treatment area with a secondary solution. The secondary solution may have an absorbent material to draw in loose ink. The example method also includes disrupting a skin barrier in the treatment area by a needle or ablative device to improve penetration of at least one of the primary solution and the secondary solution.

Abstract: The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a watersoluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound.

Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.

Abstract: Flexible solid cosmetic composition comprising sulfonate anionic surfactants, fatty esters and fatty alcohols, and cosmetic treatment method The present invention relates to an aqueous cosmetic composition in flexible solid form, comprising (i) at least 10% by weight of anionic surfactants comprising a sulfonate group, (ii) esters of fatty acid(s) comprising at least 12 carbon atoms, and (iii) fatty alcohols comprising at least 16 carbon atoms. The composition finds a particular application as a composition for cleaning or washing keratin materials, in particular the hair. The invention also relates to a cosmetic treatment method, in particular for caring for, cleaning and/or conditioning keratin materials using said composition.

Abstract: Hand sanitizers are provided with improved aesthetics and skin-conditioning effects, such that healthcare workers and others subject to high frequency hand hygiene requirements are encouraged to comply with said requirements. The hand sanitizers provide excellent antimicrobial efficacy and skin conditioning benefits that actually increase with increased frequency of use. The sanitizing compositions are hydroalcoholic, and contain a synergistic combination of skin-conditioning agents.

Abstract: The present disclosure addresses biologically active formulations for agricultural and other applications that comprise a solid growth substrate that defines an open cell matrix and an active population of one or more microorganisms adhered thereto. The formulation is configured to be applied directly to a plant growth environment and does not require additional isolation and/or processing steps that would separate the microorganisms from the solid growth substrate prior to deployment. The disclosure also addresses related methods.

Abstract: Achieving enhanced scent expression in antiperspirant compositions and methods.

Abstract: Therapeutic tea remedy mixtures in the form of beverages and ointments. Methods for making the tea remedy mixtures are described along with the benefits it provides to combat various medical ailments that frequently impair the human body.

Abstract: The invention relates to cosmetic processes and compositions for depigmenting, lightening and/or whitening keratin materials, in particular the skin, which comprises the application of a cosmetic composition comprising thiopyridinone compounds to keratin materials.

Abstract: The present invention relates to an agrochemical composition comprising a pesticide and an alkoxylate of the formula (I) R1-[AO]n—O—C(R3)(R4)—O—[CH2—CH2—O]m—R2??(I) where R1 is a C6-C32 aliphatic hydrocarbon group, R2 is a C1-C18 aliphatic hydrocarbon group, R3 and R4 are independently from another H or C1-C12 aliphatic hydrocarbon groups, AO is C2-C6 alkyleneoxy group, n is from 1 to 100, and m is from 0 to 10. The invention further relates to the alkoxylate. The invention further relates to a method of preparing the composition by bringing the alkoxylate and the pesticide into contact. Finally, the invention relates to a method of controlling phytopathogenic fungi and/or undesired plant growth and/or undesired insect or mite attack and/or for regulating the growth of plants.

Abstract: A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day.

Abstract: The present invention provides a hybrid hydrogel stabilized by multivalent cross-linking domains. The hydrogel combines inorganic nanoparticles along with an organic polymer network. The resulting material has reinforced mechanical properties and significant mineralization, and affords sustained long-term release of ions. Furthermore, ions released from the hydrogel can enhance cell spreading and promote the osteogenic differentiation of implanted cells. These promising results indicates that the provided compositions and methods are particularly appealing for bone regenerative applications.

Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are to useful in the treatment of opioid dependency/addiction and/or pain.

Abstract: A nanocomposite for detection and treatment of a target of interest including tumor cells or pathogens includes at least one nanostructure, each nanostructure having a core and a shell surrounding the core; a reporter assembled on the shell of each nanostructure; and a layer of a treating agent and a targeting agent conjugated to the reporter. In use, the nanocomposite targets to the target of interest according to the targeting agent and releases the treating agent and the nanostructure therein for therapeutic treatment of the target of interest, and the target of interest transmits at least one signature responsive to the reporter for detection of the target of interest.

Abstract: An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.

Abstract: Methods of glycoprotein production employing monosaccharides capable of producing a global increase in flux through the sialic acid pathway are provided.